Wassaifi S, Kaeffer B, Zarrouk S
Int J Mol Sci. 2025; 26(5).
PMID: 40076710
PMC: 11900927.
DOI: 10.3390/ijms26052083.
Wang H, Wei B, WuLan H, Qu B, Li H, Ren J
PLoS One. 2025; 20(3):e0316398.
PMID: 40072964
PMC: 11902060.
DOI: 10.1371/journal.pone.0316398.
Ren S, Zhang Y, Wang X, Su J, Wang X, Yuan Z
Front Immunol. 2025; 16:1526967.
PMID: 40070843
PMC: 11893557.
DOI: 10.3389/fimmu.2025.1526967.
Zhu L, Zhang J, Hu Y, Zhang Y, Wang S, Wang R
J Ginseng Res. 2025; 49(2):134-144.
PMID: 40061486
PMC: 11889374.
DOI: 10.1016/j.jgr.2024.11.001.
Huang C, Lu G, Jia Z, Yan J
Appl Biochem Biotechnol. 2025; .
PMID: 40053206
DOI: 10.1007/s12010-025-05196-2.
Bioactive lipid signaling and lipidomics in macrophage polarization: Impact on inflammation and immune regulation.
Rodriguez J, Casas J, Balboa M, Balsinde J
Front Immunol. 2025; 16:1550500.
PMID: 40028333
PMC: 11867965.
DOI: 10.3389/fimmu.2025.1550500.
Mesenchymal stem cells alleviate idiopathic pneumonia syndrome by facilitating M2 polarization via CCL2/CCR2 axis and further inducing formation of regulatory CCR2 + CD4 + T cells.
Xue C, Liu W, Li Y, Yin Y, Tang B, Zhu J
Stem Cell Res Ther. 2025; 16(1):108.
PMID: 40025564
PMC: 11872334.
DOI: 10.1186/s13287-025-04232-6.
Complex regulation of cardiac fibrosis: insights from immune cells and signaling pathways.
Rao W, Li D, Zhang Q, Liu T, Gu Z, Huang L
J Transl Med. 2025; 23(1):242.
PMID: 40022104
PMC: 11869728.
DOI: 10.1186/s12967-025-06260-5.
Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages.
Rykova E, Klimontov V, Shmakova E, Korbut A, Merkulova T, Kzhyshkowska J
Int J Mol Sci. 2025; 26(4).
PMID: 40004134
PMC: 11854991.
DOI: 10.3390/ijms26041670.
Sarcoidosis: molecular mechanisms and therapeutic strategies.
Xu D, Tao X, Fan Y, Teng Y
Mol Biomed. 2025; 6(1):6.
PMID: 39904950
PMC: 11794924.
DOI: 10.1186/s43556-025-00244-z.
Macrophage-derived extracellular vesicles as new players in chronic non-communicable diseases.
Lin F, Luo H, Wang J, Li Q, Zha L
Front Immunol. 2025; 15:1479330.
PMID: 39896803
PMC: 11782043.
DOI: 10.3389/fimmu.2024.1479330.
Characterizing the pan-cancer role of exosomal miRNAs in metastasis across cancers.
Agrawal P, Olgun G, Singh A, Gopalan V, Hannenhalli S
Comput Struct Biotechnol J. 2025; 27:252-264.
PMID: 39866667
PMC: 11763893.
DOI: 10.1016/j.csbj.2024.12.025.
Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC.
Arleo A, Montagner A, Giovannini C, Suzzi F, Piscaglia F, Gramantieri L
Biomolecules. 2025; 14(12.
PMID: 39766202
PMC: 11673139.
DOI: 10.3390/biom14121496.
CXCL8 modulates M0 macrophage proliferation and polarization to influence tumor progression in cervical cancer.
Zhao X, Yang L, Pan J, Zeng Z, Zhang T, Yang Y
Sci Rep. 2025; 15(1):790.
PMID: 39755693
PMC: 11700176.
DOI: 10.1038/s41598-024-81726-y.
Hidden features: CD36/SR-B2, a master regulator of macrophage phenotype/function through metabolism.
Chen Y, Zhang X, Huang S, Febbraio M
Front Immunol. 2025; 15:1468957.
PMID: 39742252
PMC: 11685046.
DOI: 10.3389/fimmu.2024.1468957.
Tumor microenvironment and immunotherapy for triple-negative breast cancer.
Guo Z, Zhu Z, Lin X, Wang S, Wen Y, Wang L
Biomark Res. 2024; 12(1):166.
PMID: 39741315
PMC: 11689763.
DOI: 10.1186/s40364-024-00714-6.
High glucose promotes macrophage switching to the M1 phenotype via the downregulation of STAT-3 mediated autophagy.
Zhao Y, Jiang Y, Wang F, Sun L, Ding M, Zhang L
PLoS One. 2024; 19(12):e0314974.
PMID: 39739966
PMC: 11687880.
DOI: 10.1371/journal.pone.0314974.
Signal regulatory protein α dynamically mediates macrophage polarization facilitated alleviation of ischemic diseases.
Liu H, Yuan Y, Johnson-Stephenson T, Jing C, Zhang M, Huang J
Cell Biosci. 2024; 14(1):150.
PMID: 39707436
PMC: 11662717.
DOI: 10.1186/s13578-024-01325-2.
A new perspective on macrophage-targeted drug research: the potential of in bladder cancer immunotherapy.
Zhao Z, Jia H, Sun Z, Li Y, Liu L
Front Immunol. 2024; 15:1485109.
PMID: 39691708
PMC: 11649672.
DOI: 10.3389/fimmu.2024.1485109.
Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers.
Xu Q, Shao D
Front Immunol. 2024; 15:1487610.
PMID: 39691707
PMC: 11649667.
DOI: 10.3389/fimmu.2024.1487610.